Approach
Tendinopathy is debilitating for patients and costly to healthcare systems. We are leveraging microRNA-29a to develop therapies that can help patients reclaim their active lives and reduce system burden.
Our microRNA-29a technology
Our breakthrough technology restores miR-29a, effectively suppressing tendinopathy related disease pathways, and heals damaged tendons.
What are microRNAs?
microRNAs (miRNAs) are double-stranded RNA molecules that regulate cellular pathways by preventing the messenger RNAs they target from being translated into proteins.
There approximately 2300 different miRNA species expressed in humans, each capable of regulating hundreds of other genes, fine-tuning the expression of biological pathways in health and disease. Dysregulation of miRNA expression, either too much or too little, can have a profound impact on health.
Multi-pathway regulators
As multi-pathway regulators, miRNA-based therapies are ideally suited for the treatment of complex multigenic disorders where conventional single-target therapies have failed.
The scientists who discovered microRNAs, Victor Ambros and Gary Ruvkun, were awarded the Nobel prize for medicine in 2024.
